• Career
  • Support
  • Contact Us
Menu
  • Career
  • Support
  • Contact Us
  • Solutions
    • Medical Device Services
    • Medical Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Menu
  • Solutions
    • Medical Device Services
    • Medical Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Search
Close
Menu
  • Solutions
    • Medical Device Services
    • Medical Research Services
  • Get Started
    • Get a Quote
    • Get Set Up
  • News & Events
    • News
    • Events
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us
  • All Webinars

Muscle Fat Replacement and Functional Decline in Neuromuscular Disorders – Quantitative Skeletal Muscle MRI in Clinical Trials

  • The recorded webinar will soon be uploaded. Please come back in a couple of days.

You need a link to access the webinar

You will get an access link sent to your e-mail.


    Drug development in neuromuscular disorders needs robust biomarker and clinical endpoints to study drug efficacy in early and late stage trials. Ultimately, functional decline and motor disability are the main clinical manifestations of neuromuscular disorders (NMD) and used for approval of novel therapeutics. However, assessment of changes in neurological function is associated with large variability and many NMDs are slowly progressive, thus limiting its feasibility as efficacy endpoint in early clinical development.

    One of the most promising efficacy biomarkers in neuromuscular disorders for early clinical development is skeletal muscle MRI. The recent development of quantitative skeletal MRI biomarkers, describing the extent of muscle atrophy and muscle fat infiltration and replacement, has enabled the detection and measurement of NMD earlier and more precisely compared to clinical endpoints. Standardized quantitative skeletal muscle MRI has been used to objectively evaluate NMD across different disease stages and measure longitudinal changes in diseases with complex onset patterns and slow progression such as FSHD (facioscapulomuscular dystrophy) and DMD (Duchenne Muscular Dystrophy).

    In this webinar, three experts will discuss various aspects of MRI biomarker development in NMD with a special focus on recent developments and experiences with MRI skeletal muscle biomarkers in DMD and FSHD:

    Sarah Sherlock, PhD, Pfizer – Experience of using MRI biomarkers in Duchenne Muscular Dystrophy trials

    Diego Cadavid, MD, Fulcrum Therapeutics – Opportunities and challenges with MRI biomarker development for FSHD drug trials

    Per Widholm, MD, AMRA Medical Research – Standardized whole-body MRI, precise monitoring of muscular dystrophies with heterogeneous pattern of onset and disease progression

    Share on twitter
    Share on linkedin
    Share on facebook
    Share on email
    Webinar Date
    • 7 October 2020
    Sarah Sherlock, PhD
    Director Clinical and Translational Imaging
    Pfizer
    Read more
    Sarah Sherlock, PhD

    Director Clinical and Translational Imaging

    Pfizer

    Diego Cadavid, MD
    Senior Vice President, Clinical Development
    Fulcrum Therapeutics
    Read more
    Diego Cadavid, MD

    Senior Vice President, Clinical Development

    Fulcrum Therapeutics

    Per Widholm, MD
    Lead Scientist, MSK
    AMRA Medical Research
    Read more
    Per Widholm, MD

    Lead Scientist, MSK

    AMRA Medical Research

    What you will learn
    •
    How water and fat separated MRI has been used to describe disease stage and progression in neuromuscular disorders
    •
    Current examples of how quantitative MRI is used in neuromuscular trials
    •
    How whole-body MRI could improve the detection of treatment effect in NMD trials
    Who should attend?
    •
    Chief Medical Officer
    •
    Chief Executive Officer
    •
    Principal Investigator
    •
    Medical Director
    •
    Research Nurse
    •
    Clinical Director
    •
    Clinical Project Manager
    •
    Imaging Specialist
    •
    Clinical Operations
    •
    Clinical Development Manager
    •
    Procurement Manager
    •
    Statistician
    •
    Data Manager
    •
    Regulatory Coordinator
    •
    Business Development

    AMRA Medical is a digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition analysis, delivering multiple fat and muscle biomarkers with unrivaled accuracy and precision – all from a rapid whole-body MRI scan.

    AMRA offers medical device and medical research services to support transformative care and vital decision-making, from clinical research to clinical care.

    Contact

    • info@amramedical.com
    • +46 (0) 13 16 26 00
    • Contact Our Support
    Follow us
    Linkedin Twitter Facebook

    Newsletter

      • Data Privacy Policy
      • Cookies
      Menu
      • Data Privacy Policy
      • Cookies

      © 2022 AMRA Medical AB

      By using our site, you acknowledge that you have read and understood our privacy policy. We use cookies to ensure you have the best browsing experience on our website.
      Accept & Close

      Book a Meeting